Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
12,64 USD | +3,31% | +4,51% | -15,37% |
Attività
Numero di dipendenti: 1 453
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Tumor Treating Fields
100,0
%
| 538 | 100,0 % | 509 | 100,0 % | -5,30% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
68,7
%
| 407 | 75,7 % | 350 | 68,7 % | -14,05% |
Germany
11,8
%
| 46 | 8,6 % | 60 | 11,8 % | +30,55% |
Others
8,7
%
| 0 | 0,0 % | 44 | 8,7 % | - |
Japan
6,2
%
| 33 | 6,1 % | 32 | 6,2 % | -3,40% |
Greater China
4,6
%
| 21 | 4,0 % | 23 | 4,6 % | +8,87% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Asaf Danziger
CEO | Chief Executive Officer | 56 | 01/01/02 |
Ashley Cordova
DFI | Director of Finance/CFO | 45 | 01/06/14 |
Moshe Giladi
CTO | Chief Tech/Sci/R&D Officer | - | - |
Nicolas Leupin
CTO | Chief Tech/Sci/R&D Officer | 50 | 04/01 |
Chief Operating Officer | 66 | 05/01/12 | |
Ingrid Goldberg
IRC | Investor Relations Contact | - | 01/07/21 |
Barak Ben Arye
LAW | General Counsel | 48 | 01/01/18 |
Corporate Officer/Principal | - | - | |
Uri Weinberg
PRN | Corporate Officer/Principal | 46 | 01/03/08 |
Michael Puri
HRO | Human Resources Officer | 55 | 01/09/23 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Bill Doyle
CHM | Chairman | 61 | 01/01/04 |
Kin Yip Leung
BRD | Director/Board Member | 62 | 05/08/11 |
David Hung
BRD | Director/Board Member | 66 | 31/05/18 |
Timothy Scannell
BRD | Director/Board Member | 60 | 05/02/21 |
Jeryl Hilleman
BRD | Director/Board Member | 66 | 25/07/18 |
Tony Vernon
BRD | Director/Board Member | 68 | 01/01/06 |
Asaf Danziger
CEO | Chief Executive Officer | 56 | 01/01/02 |
Martin Madden
BRD | Director/Board Member | 64 | 10/05/17 |
Kristin Stafford
BRD | Director/Board Member | 42 | 28/03/23 |
Allyson Ocean
BRD | Director/Board Member | 52 | 23/02/23 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 107 606 309 | 97 642 935 ( 90,74 %) | 0 | 90,74 % |
Coordinate società
NovoCure Ltd.
No. 4 The Forum Grenville Street
JE2 4UF, St. Helier
+44 15 3475 6700
http://www.novocure.comSettore
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
-15,37% | 1,36 Mrd | |
+73,17% | 12,38 Mrd | |
-18,74% | 7,92 Mrd | |
+16,15% | 7,2 Mrd | |
+4,81% | 5,84 Mrd | |
+5,99% | 5,01 Mrd | |
+27,07% | 4,53 Mrd | |
-21,67% | 3,88 Mrd | |
-40,82% | 2,23 Mrd | |
+1,49% | 2,02 Mrd |
- Borsa valori
- Azioni
- Azione NVCR
- Società NovoCure Limited